CAI
Clinical Asset Index
by VOS Supply Group
Drugs · acquisition-cost intelligence

DECONEX DMX

Dextromethorphan Hydrobromide, Guaifenesin, Phenylephrine Hydrochloride· ingredient dextromethorphanAdrenergic and dopaminergic agents· DEXTROMETHORPHAN HYDROBROMIDE 17.5 mg/1; GUAIFENESIN 400 mg/1
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per EA
$0.67170
NADAC — pharmacy acquisition cost, not a retail/cash price

Acquisition-cost history

Weekly NADAC per EA — the trend nobody else shows. 4 weeks.

2025-12-172026-03-18

Same-ingredient options by acquisition cost

Other dextromethorphan products, cheapest acquisition cost first. Per EA — confirm strength/form equivalence before switching.

ProductNADAC / EAvs this
ACTINEL Diabetic$0.01104−$0.66070
adult cough and chest congestion$0.01973−$0.65200
BACTIMICINA COUGH AND COLD$0.02085−$0.65080
7 Select Maximum Strength$0.02142−$0.65030
Adult Cough Relief$0.02292−$0.64880
Promethazine DM$0.03852−$0.63320
AMAZON Childrens Multi Symptom Cold$0.04678−$0.62490
12 HR RELIEF COUGH DM$0.06804−$0.60370

Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.